New Toolkit Helps Community Pharmacies Launch Harm Reduction Services
A new toolkit from the University of Pittsburgh School of Pharmacy offers community pharmacies a practical, step-by-step guide to implementing harm reduction services — from assembling supply kits and training staff to marketing services and integrating them into existing workflows. Here's why it matters for pharmacist-led OUD care.
Pharmacists Are Critical In Opioid Use Disorder Care - Pharmacy Practice News
The SUPPORT for Patients and Communities Reauthorization Act, signed into law in 2025, grants pharmacists greater autonomy to prescribe buprenorphine for opioid use disorder after completing specialized training. In a new article in Pharmacy Practice News, two clinical pharmacists describe how they are already providing OUD care across VA, hospital, and community settings — and why state scope-of-practice laws must evolve to match what federal law now permits.
How Pharmacists Could Be Key to Addressing the Opioid Crisis
Optimal adherence to long-acting injectable buprenorphine (BUP-XR or Sublocade®) for opioid use disorder saves $15,017 per patient annually by drastically reducing costly emergency department visits and detoxification events. This research supports the economic benefits of paying community pharmacists to administer long-acting injections, effectively improving treatment access while lowering overall healthcare spending.
Bridging the Knowledge Gap: Why ECHO Idaho is a Game-Changer for Idaho Clinicians
A recent update from the University of Idaho highlights the critical role of Project ECHO Idaho in equipping healthcare providers with the tools to manage these evolving challenges. For pharmacists interested in delivering low-barrier MOUD care, this program offers a unique, no-cost pathway to expertise.